KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Enterprise Value (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Enterprise Value readings, the most recent being -$3.7 billion for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 121.12% to -$3.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.7 billion, a 121.12% decrease, with the full-year FY2025 number at -$3.6 billion, down 20.0% from a year prior.
  • Enterprise Value hit -$3.7 billion in Q1 2026 for Teva Pharmaceutical Industries, down from -$3.6 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$1.3 billion in Q1 2022 to a low of -$3.7 billion in Q1 2026.
  • Median Enterprise Value over the past 5 years was -$2.1 billion (2024), compared with a mean of -$2.3 billion.
  • Biggest five-year swings in Enterprise Value: soared 38.0% in 2025 and later crashed 121.12% in 2026.
  • Teva Pharmaceutical Industries' Enterprise Value stood at -$2.0 billion in 2022, then crashed by 60.74% to -$3.2 billion in 2023, then grew by 8.25% to -$3.0 billion in 2024, then decreased by 20.0% to -$3.6 billion in 2025, then dropped by 5.21% to -$3.7 billion in 2026.
  • The last three reported values for Enterprise Value were -$3.7 billion (Q1 2026), -$3.6 billion (Q4 2025), and -$2.2 billion (Q3 2025) per Business Quant data.